Article Text

Download PDFPDF
Cohort study
Of people admitted within 2 h of mild/improving stroke, 31% do not receive rtPA, although many of these people have poor outcomes
  1. Joshua Z Willey
  1. Division of Stroke, Department of Neurology, Columbia University, New York, USA
  1. Correspondence to Joshua Z Willey
    Division of Stroke, Department of Neurology, Columbia University, 710 West 168th street, New York, NY 10032, USA; Jzw2{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Few patients with acute ischaemic stroke receive intravenous recombinant tissue plasminogen activator (rtPA), with the main exclusion criterion being hospital arrival after 4½ h.1 The second most common exclusion criterion from rtPA treatment, which is present in approximately 1/3 of all patients, is a mild or rapidly improving syndrome, termed ‘too good to treat’.2 Uncertainty remains as to whether these patients …

View Full Text


  • Competing interests None.